ES2656000T3 - Anticuerpos frente a CGRP - Google Patents
Anticuerpos frente a CGRP Download PDFInfo
- Publication number
- ES2656000T3 ES2656000T3 ES11792989.3T ES11792989T ES2656000T3 ES 2656000 T3 ES2656000 T3 ES 2656000T3 ES 11792989 T ES11792989 T ES 11792989T ES 2656000 T3 ES2656000 T3 ES 2656000T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- antibodies against
- lcdr3
- lcdr1
- lcdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- DNKYDHSONDSTNJ-XJVRLEFXSA-N chembl1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un anticuerpo frente a CGRP humano técnicamente diseñado que comprende una región variable de la cadena ligera (LCVR) y una región variable de la cadena pesada (HCVR), en el que dicha LCVR comprende las secuencias de aminoácidos de LCDR1, LCDR2, LCDR3 y la HCVR comprende las secuencias de aminoácidos de HCDR1, HCDR2, HCDR3, en el que LCDR1 es RASKDISKYLN (SEQ ID NO: 6), LCDR2 es YTSGYHS (SEQ ID NO: 7), LCDR3 es QQGDALPPT (SEQ ID NO: 5), HCDR1 es GYTFGNYWMQ (SEQ ID NO: 12), HCDR2 es AIYEGTGKTVYIQKFAD (SEQ ID NO: 16) y HCDR3 es LSDYVSGFGY (SEQ ID NO: 39).
Description
X1 es Q, R o K; X2 es D o P; X3 es D o S; X4 es N o K; y X5 es G o E.
- Anticuerpo
- LCDR1 LCDR2 LCDR3
- I
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGDTRYIQKFAG (SEQ ID NO: 13) LSDYVSGFSY (SEQ ID NO:14)
- II
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAG (SEQ ID NO: 15 LSDYVSGFSY (SEQ ID NO:14)
- III
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAD (SEQ ID NO: 16) LSDYVSGFGY (SEQ ID NO:39)
- IV
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAG (SEQ ID NO: 15) LSDYVSGFGY (SEQ ID NO:39)
- V
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGKTVYIQKFAG (SEQ ID NO: 15) LSDYVSGFGY (SEQ ID NO:39)
- consenso
- GYTFGNYWMQ (SEQ ID NO:12) AIYEGTGX6TX7YIQKFAX8 (SEQ ID NO:37) LSDYVSGFX9Y (SEQ ID NO:38)
X6 es K o D; X7 es V o R; X8 es D oG; y X9 es G o S.
11
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35332310P | 2010-06-10 | 2010-06-10 | |
| US353323P | 2010-06-10 | ||
| PCT/US2011/039381 WO2011156324A1 (en) | 2010-06-10 | 2011-06-07 | Cgrp antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2656000T3 true ES2656000T3 (es) | 2018-02-22 |
Family
ID=45096388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11792989.3T Active ES2656000T3 (es) | 2010-06-10 | 2011-06-07 | Anticuerpos frente a CGRP |
| ES17201603T Active ES2930321T3 (es) | 2010-06-10 | 2011-06-07 | Anticuerpos frente a CGRP |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17201603T Active ES2930321T3 (es) | 2010-06-10 | 2011-06-07 | Anticuerpos frente a CGRP |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9073991B2 (es) |
| EP (2) | EP2579894B1 (es) |
| JP (2) | JP6021806B2 (es) |
| KR (1) | KR101489566B1 (es) |
| CN (2) | CN104292332B (es) |
| AR (1) | AR081434A1 (es) |
| AU (1) | AU2011265050B2 (es) |
| BR (1) | BR112012031501B1 (es) |
| CA (1) | CA2802102C (es) |
| CY (2) | CY1119789T1 (es) |
| DK (1) | DK2579894T3 (es) |
| EA (1) | EA022931B1 (es) |
| ES (2) | ES2656000T3 (es) |
| HK (1) | HK1203211A1 (es) |
| HR (1) | HRP20171992T1 (es) |
| HU (2) | HUE038135T2 (es) |
| IL (2) | IL222885B (es) |
| JO (1) | JO3330B1 (es) |
| LT (2) | LT2579894T (es) |
| LU (1) | LUC00112I2 (es) |
| ME (1) | ME02862B (es) |
| MX (2) | MX363209B (es) |
| NL (1) | NL300979I2 (es) |
| NO (2) | NO2579894T3 (es) |
| NZ (1) | NZ603607A (es) |
| PL (1) | PL2579894T3 (es) |
| PT (1) | PT2579894T (es) |
| RS (1) | RS56638B1 (es) |
| SG (1) | SG185648A1 (es) |
| SI (1) | SI2579894T1 (es) |
| TW (1) | TWI423818B (es) |
| UA (1) | UA109658C2 (es) |
| WO (1) | WO2011156324A1 (es) |
| ZA (1) | ZA201208996B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57194B1 (sr) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals Int Gmbh | Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje |
| MX2010009722A (es) | 2008-03-04 | 2010-09-30 | Pfizer Ltd | Procedimiento de tratamiento del dolor cronico. |
| EP3165236B1 (en) | 2009-08-28 | 2022-03-16 | Teva Pharmaceuticals International GmbH | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
| AR081434A1 (es) * | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
| KR101965461B1 (ko) | 2011-05-20 | 2019-04-04 | 앨더바이오 홀딩스 엘엘씨 | 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도 |
| LT3495392T (lt) * | 2011-05-20 | 2021-09-27 | H. Lundbeck A/S | Anti-cgrp kompozicijos ir jų panaudojimas |
| NZ732875A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| EP2888283B1 (en) | 2012-08-24 | 2018-09-19 | The Regents of The University of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| JP6568099B2 (ja) | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
| MD20170055A2 (ro) | 2014-10-24 | 2017-09-30 | Merck Sharp & Dohme Corp | Co-agonişti ai receptorilor glucagonului şi GLP-1 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| KR20180054851A (ko) * | 2015-10-30 | 2018-05-24 | 일라이 릴리 앤드 캄파니 | 항-cgrp/항-il-23 이중특이적 항체 및 그의 용도 |
| CN105483091A (zh) * | 2015-12-29 | 2016-04-13 | 天津三箭生物技术股份有限公司 | 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| KR20180091930A (ko) * | 2016-01-28 | 2018-08-16 | 일라이 릴리 앤드 캄파니 | Cgrp 항체 및 그의 용도 |
| US11492386B2 (en) | 2016-02-01 | 2022-11-08 | Eli Lilly And Company | Parathyroid hormone-anti-RANKL antibody fusion compounds |
| US10688181B2 (en) | 2016-06-27 | 2020-06-23 | The Regents Of The University Of California | Cancer treatment combinations |
| EP3515488A1 (en) | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating cluster headache |
| BR112019005823A2 (pt) | 2016-09-23 | 2019-06-25 | Teva Pharmaceuticals Int Gmbh | tratamento para enxaqueca refratária |
| JP7195262B2 (ja) | 2017-03-02 | 2022-12-23 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法 |
| AR111845A1 (es) | 2017-05-03 | 2019-08-28 | Lilly Co Eli | Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos |
| CA3066893A1 (en) * | 2017-06-21 | 2018-12-27 | Cephalon, Inc. | Cation exchange chromatography wash buffer |
| TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| CA3087951A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
| WO2019231800A1 (en) | 2018-05-31 | 2019-12-05 | Eli Lilly And Company | Anti-cgrp antibodies for treating menstrual-related migraines |
| MA53436A (fr) | 2018-08-22 | 2021-12-01 | Lilly Co Eli | Anticorps anti-cgrp pour patients résistants au traitement |
| WO2020146527A1 (en) | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
| EP3744400A1 (en) * | 2019-05-28 | 2020-12-02 | Etablissement Français du Sang | Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml) |
| WO2020239014A1 (zh) * | 2019-05-30 | 2020-12-03 | 山东博安生物技术有限公司 | 抗cgrp抗体及其应用 |
| EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| US20240139171A1 (en) | 2021-03-02 | 2024-05-02 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
| WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
| CN117586390A (zh) * | 2022-08-11 | 2024-02-23 | 上海君实生物医药科技股份有限公司 | 抗cgrp抗体及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1992019759A1 (en) * | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| JP4976376B2 (ja) | 2005-04-08 | 2012-07-18 | メディミューン，エルエルシー | 哺乳動物メタニューモウイルスに対する抗体 |
| RS57194B1 (sr) * | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals Int Gmbh | Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje |
| WO2007076336A1 (en) | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
| EP2265288B1 (en) * | 2008-03-04 | 2016-05-11 | Labrys Biologics Inc. | Methods of treating inflammatory pain |
| MX2010009722A (es) * | 2008-03-04 | 2010-09-30 | Pfizer Ltd | Procedimiento de tratamiento del dolor cronico. |
| AR081434A1 (es) * | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
-
2011
- 2011-05-31 AR ARP110101867A patent/AR081434A1/es active IP Right Grant
- 2011-05-31 JO JOP/2011/0177A patent/JO3330B1/ar active
- 2011-06-03 TW TW100119683A patent/TWI423818B/zh active
- 2011-06-07 SI SI201131359T patent/SI2579894T1/en unknown
- 2011-06-07 DK DK11792989.3T patent/DK2579894T3/en active
- 2011-06-07 MX MX2016005150A patent/MX363209B/es unknown
- 2011-06-07 WO PCT/US2011/039381 patent/WO2011156324A1/en active Application Filing
- 2011-06-07 JP JP2013514281A patent/JP6021806B2/ja active Active
- 2011-06-07 MX MX2012014480A patent/MX340999B/es active IP Right Grant
- 2011-06-07 US US13/154,538 patent/US9073991B2/en active Active
- 2011-06-07 EP EP11792989.3A patent/EP2579894B1/en active Active
- 2011-06-07 RS RS20171265A patent/RS56638B1/sr unknown
- 2011-06-07 PL PL11792989T patent/PL2579894T3/pl unknown
- 2011-06-07 BR BR112012031501-3A patent/BR112012031501B1/pt active IP Right Grant
- 2011-06-07 NZ NZ603607A patent/NZ603607A/en unknown
- 2011-06-07 CA CA2802102A patent/CA2802102C/en active Active
- 2011-06-07 AU AU2011265050A patent/AU2011265050B2/en active Active
- 2011-06-07 PT PT117929893T patent/PT2579894T/pt unknown
- 2011-06-07 ME MEP-2017-280A patent/ME02862B/me unknown
- 2011-06-07 HU HUE11792989A patent/HUE038135T2/hu unknown
- 2011-06-07 CN CN201410474677.9A patent/CN104292332B/zh active Active
- 2011-06-07 EA EA201270769A patent/EA022931B1/ru not_active IP Right Cessation
- 2011-06-07 NO NO11792989A patent/NO2579894T3/no unknown
- 2011-06-07 CN CN201180028611.1A patent/CN102946905B/zh active Active
- 2011-06-07 ES ES11792989.3T patent/ES2656000T3/es active Active
- 2011-06-07 ES ES17201603T patent/ES2930321T3/es active Active
- 2011-06-07 KR KR1020127032068A patent/KR101489566B1/ko active IP Right Grant
- 2011-06-07 SG SG2012084885A patent/SG185648A1/en unknown
- 2011-06-07 EP EP17201603.2A patent/EP3318272B1/en active Active
- 2011-06-07 LT LTEP11792989.3T patent/LT2579894T/lt unknown
- 2011-07-06 UA UAA201212663A patent/UA109658C2/ru unknown
-
2012
- 2012-11-05 IL IL222885A patent/IL222885B/en active Protection Beyond IP Right Term
- 2012-11-28 ZA ZA2012/08996A patent/ZA201208996B/en unknown
-
2015
- 2015-04-20 HK HK15103793.6A patent/HK1203211A1/xx unknown
- 2015-06-04 US US14/730,270 patent/US9505838B2/en active Active
- 2015-11-02 IL IL242409A patent/IL242409B/en active IP Right Grant
-
2016
- 2016-06-28 JP JP2016127666A patent/JP6466883B2/ja active Active
- 2016-11-02 US US15/341,166 patent/US20170073403A1/en not_active Abandoned
-
2017
- 2017-12-21 HR HRP20171992TT patent/HRP20171992T1/hr unknown
-
2018
- 2018-01-18 CY CY20181100064T patent/CY1119789T1/el unknown
-
2019
- 2019-04-02 CY CY2019017C patent/CY2019017I2/el unknown
- 2019-04-02 HU HUS1900020C patent/HUS1900020I1/hu unknown
- 2019-04-05 NO NO2019017C patent/NO2019017I1/no unknown
- 2019-04-09 LU LU00112C patent/LUC00112I2/fr unknown
- 2019-04-11 NL NL300979C patent/NL300979I2/nl unknown
- 2019-04-12 LT LTPA2019011C patent/LTC2579894I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2656000T3 (es) | Anticuerpos frente a CGRP | |
| ES2564252T3 (es) | Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| ES2543174T3 (es) | Composición medicinal para el tratamiento y/o la prevención del cáncer | |
| HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| AR081427A1 (es) | Metodo para preparar anticuerpos con propiedades mejoradas | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| RS54111B1 (en) | ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| PE20091261A1 (es) | Anticuerpos anti-hepcidina | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| NZ702494A (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| RU2011142183A (ru) | Средство для лечения ревматоидного артрита | |
| HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 |